Tobevibart + Elebsiran + Bulevirtide

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Viral Hepatitis

Conditions

Viral Hepatitis

Trial Timeline

Aug 5, 2025 → Jul 1, 2030

NCT ID

NCT07142811

About Tobevibart + Elebsiran + Bulevirtide

Tobevibart + Elebsiran + Bulevirtide is a phase 2 stage product being developed by Vir Biotechnology for Viral Hepatitis. The current trial status is active. This product is registered under clinical trial identifier NCT07142811. Target conditions include Viral Hepatitis.

What happened to similar drugs?

1 of 6 similar drugs in Viral Hepatitis were approved

Approved (1) Terminated (1) Active (4)

✅Grazoprevir plus ElbasvirMerckApproved

🔄Tozorakimab + PlaceboAstraZenecaPhase 3

🔄V503 + GARDASILMerckPhase 3

🔄Tobevibart + ElebsiranVir BiotechnologyPhase 3

🔄Tobevibart + Elebsiran + BulevirtideVir BiotechnologyPhase 3

❌Azithromycin plus hydroxychloroquineIterum TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07142811	Phase 2	Active	Aug 5, 2025	Jul 1, 2030	Viral Hepatitis
NCT07128550	Phase 3	Recruiting	Jul 30, 2025	Jul 1, 2031	Viral Hepatitis

Competing Products

17 competing products in Viral Hepatitis

See all competitors

Product	Company	Stage	Hype Score
Tozorakimab + Placebo	AstraZeneca	Phase 3	47
V503 + GARDASIL	Merck	Phase 3	40
Grazoprevir plus Elbasvir	Merck	Approved	43
Elbasvir + Placebo	Merck	Phase 1	29
PF-07304814 + Placebo	Pfizer	Phase 1	29
Rifabutin + Rifabutin + Atazanavir + Ritonavir	Bristol Myers Squibb	Phase 1	29
Hepatitis C Immune Globulin Intravenous (Human) 5%	ADMA Biologics	Phase 2	21
Tobevibart + Elebsiran	Vir Biotechnology	Phase 3	38
Tobevibart + Elebsiran + Bulevirtide	Vir Biotechnology	Phase 3	41
UV-4B 3 mg + UV-4B 10 mg + UV-4B 30 mg + UV-4B 90 mg + UV-4B 180 mg + UV-4B 360 mg + UV-4B 720 mg + UV-4B 1000 mg + Placebo	Emergent BioSolutions	Phase 1	19
PXVX0047 Vaccine + Teva Ad4/Ad7 Vaccine	Emergent BioSolutions	Phase 1	11
UV-4B 30 mg oral solution + UV-4B 75 mg oral solution + UV-4B 150 mg oral solution + UV-4B X mg (dose to be determined) oral solution + UV-4B Y mg (dose to be determined) oral solution + Placebo	Emergent BioSolutions	Phase 1	11
ST-246 400 mg + ST-246 600 mg + Placebo	SIGA Technologies	Phase 2	25
ST-246 Days 1 - 3 + ST-246 Days 11 - 13	SIGA Technologies	Phase 1	19
Ibudilast + Placebo	MediciNova	Phase 2	25
PrEP-001	hVIVO	Phase 2	25
Azithromycin plus hydroxychloroquine	Iterum Therapeutics	Phase 3	22